Pros and cons of using aberrant glycosylation as companion biomarkers for therapeutics in cancer

BMB Reports

Volumn 44, Issue 12, 2011, Pages 765-771

  Kang, Jeong Gu ^a   Ko, Jeong Heon ^a   Kim, Yong Sam ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Aberrant glycosylation; Cancer diagnostics; Companion biomarker

Indexed keywords

POLYSACCHARIDE; TUMOR MARKER;

CHEMISTRY; GENETICS; GLYCOSYLATION; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; SHORT SURVEY;

GLYCOSYLATION; HUMANS; NEOPLASMS; POLYSACCHARIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 84863277445     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2011.44.12.765     Document Type: Short Survey

References (52)

1. World Health Organization Report (2009) Global health risks: mortality and burden of disease attributable to selected major risks.
2. Ross, J. S. and Ginsburg, G. S. (2002) Integrating diagnostics and therapeutics: revolutionizing drug discovery and patient care. Drug. Discov. Today 7, 859-864.
3. Nowell, P. and Hungerford, D. (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497.
4. Lugo, T. G., Pendergast, A. M., Muller, A. J. and Witte, O. N. (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247, 1079-1082.
5. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J. and Lydon, N. B. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566.
6. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A. and McGuire W. L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.
7. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J. and Norton, L. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792.
8. Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., Shak, S., Stewart, S. J. and Press, M. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726.
9. Herbst. R. S., Fukuoka, M. and Baselga, J. (2004) Gefitinib-a novel targeted approach to treating cancer. Nat. Rev. Cancer 4, 956-965.
10. Ferrara, N. (2005) VEGF as a therapeutic target in cancer. Oncology 69 (Suppl. 3), 11-16.
11. Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S., Watanabe, H., Kurashina, K., Hatanaka, H., Bando, M., Ohno, S., Ishikawa, Y., Aburatani, H., Niki, T., Sohara, Y., Sugiyama, Y. and Mano, H. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566.
12. Vo, T. T. and Letai, A. (2010) BH3-only proteins and their effects on cancer. Adv. Exp. Med. Biol. 687, 49-63.
13. Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., Martin, N. M., Jackson, S. P., Smith, G. C. and Ashworth, A. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921.
14. Masamura, S., Santner, S. J., Heitjan, D. F. and Santen, R. J. (1995) Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J. Clin. Endocrinol. Metab. 80, 2918-2925.
15. Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., Scott, M. A., Erber, W. N. and Green, A. R.; Cancer Genome Project (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061.
16. Liu, P., Cheng, H., Roberts, T. M. and Zhao, J. J. (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627-644.
17. Swaroop, A., Chew, E. Y., Bowes, Rickman, C. and Abecasis, G. R. (2009) Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. Annu. Rev. Genomics Hum. Genet. 10, 19-43.
18. Johnson, A. D. and O'Donnell, C. J. (2009) An open access database of genome-wide association results. BMC Med. Genet. 10, 6.
19. Reddy, E. P., Reynold, R. K., Santos, E. and Barbacid, M. A. (1982) A point mutation is responsible for the acquisition of transforming properties of the T24 human bladder carcinoma oncogene. Nature 300, 149-152.
20. Capon, D. J., Seeburg, P. H., McGrath, J. P., Hayflick, J. S., Edman, U., Levinson, A. D. and Goeddel, D. V. (1983) Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations. Nature 304, 507-513.
21. Bos, J. L., Toksoz, D., Marshall, C. J., Verlaan-de Vries, M., Veeneman, G. H., van der Eb, A. J., van Boom, J. H., Janssen, J. W. and Steenvoorden, A. C. (1985) Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia. Nature 315, 726-730.
22. Lièvre, A., Bachet, J. B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., André, T., Bibeau, F., Diebold, M. D., Rougier, P., Ducreux, M., Tomasic, G., Emile, J. F., Penault-Llorca, F. and Laurent-Puig, P. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26, 374-379.
23. Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., Patterson, S. D. and Chang, D. D. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626-1634.
24. Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S. L., Herbst, R. S., Ince, W. L., Jänne, P. A., Januario, T., Johnson, D. H., Klein, P., Miller, V. A., Ostland, M. A., Ramies, D. A., Sebisanovic, D., Stinson, J. A., Zhang, Y. R., Seshagiri, S. and Hillan, K. J. (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23, 5900-5909.
25. The Food and Drug Administration (2005) Drug-Diagnostic Co-Development Concept Paper (Draft-Not for Implementation).
26. Holt, G. D. and Hart, G. W. (1986) The subcellular distribution of terminal N-acetylglucosamine moieties. Localization of a novel protein-saccharide linkage, O-linked GlcNAc. J. Biol. Chem. 261, 8049-8057.
27. Wang, Z., Gucek, M. and Hart, G. W. (2008) Cross-talk between GlcNAcylation and phosphorylation: site-specific phosphorylation dynamics in response to globally elevated O-GlcNAc. Proc. Natl. Acad. Sci. U.S.A. 105, 13793-13798.
28. Maeda, Y. and Kinoshita, T. (2011) Structural remodeling, trafficking and functions of glycosylphosphatidylinositol-anchored proteins. Prog. Lipid. Res. 50, 411-424.
29. Yu, R. K., Tsai, Y. T., Ariga, T. and Yanagisawa, M. (2011) Structures, biosynthesis., functions of gangliosides-an overview. J. Oleo. Sci. 60, 537-544.
30. Helenius, A. and Aebi, M. (2001) Intracellular functions of N-linked glycans. Science 291, 2364-2369.
31. Roth, J. (2002) Protein N-glycosylation along the secretory pathway: relationship to organelle topography and function, protein quality control, and cell interactions. Chem. Rev. 102, 285-303.
32. Ko, J. H., Miyoshi, E., Noda, K., Ekuni, A., Kang, R., Ikeda, Y. and Taniguchi, N. (1999) Regulation of the GnT-V promoter by transcription factor Ets-1 in various cancer cell lines. J. Biol. Chem. 274, 22941-22948.
33. Dall'Olio, F. and Chiricolo, M. (2001) Sialyltransferases in cancer. Glycoconj. J. 18, 841-850.
34. Cazet, A., Julien, S., Bobowski, M., Krzewinski-Recchi, M. A., Harduin-Lepers, A., Groux-Degroote, S. and Delannoy, P. (2010) Consequences of the expression of sialylated antigens in breast cancer. Carbohydr. Res. 345, 1377-1383.
35. Itzkowitz, S. H., Bloom, E. J., Kokal, W. A., Modin, G., Hakomori, S. and Kim, Y. S. (1990) Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 66, 1960-1966.
36. Ma, X. C., Terata, N., Kodama, M., Jancic, S., Hosokawa, Y. and Hattori, T. (1993) Expression of sialyl-Tn antigen is correlated with survival time of patients with gastric carcinomas. Eur. J. Cancer 29A, 1820-1823.
37. Burchell, J. M., Mungul, A. and Taylor-Papadimitriou, J. (2001) O-linked glycosylation in the mammary gland: changes that occur during malignancy. J. Mammary Gland Biol. Neoplasia 6, 355-364.
38. Kim, Y. S., Hwang, S. Y., Kang, H. Y., Sohn, H., Oh, S., Kim, J. Y., Yoo, J. S., Kim, Y. H., Kim, C. H., Jeon, J. H., Lee, J. M., Kang, H. A., Miyoshi, E., Taniguchi, N., Yoo, H. S. and Ko, J. H. (2008) Functional proteomics study reveals that N-Acetylglucosaminyltransferase V reinforces the invasive/metastatic potential of colon cancer through aberrant glycosylation on tissue inhibitor of metalloproteinase-1. Mol. Cell. Proteomics. 7, 1-14.
39. Ben-David, T., Sagi-Assif, O., Meshel, T., Lifshitz, V., Yron, I. and Witz, I. P. (2008) The involvement of the sLe-a selectin ligand in the extravasation of human colorectal carcinoma cells. Immunol. Lett. 116, 218-224.
40. Shirure, V. S., Henson, K. A., Schnaar, R. L., Nimrichter, L. and Burdick, M. M. (2011) Gangliosides expressed on breast cancer cells are E-selectin ligands. Biochem. Biophys. Res. Commun. 406, 423-429.
41. Chen, G., Howe, A. G., Xu, G., Fröhlich, O., Klein, J. D. and Sands, J. M. (2011) Mature N-linked glycans facilitate UT-A1 urea transporter lipid raft compartmentalization. FASEB J. In press.
42. Hollenstein, K., Dawson, R. J. and Locher, K. P. (2007) Structure and mechanism of ABC transporter proteins. Curr. Opin. Struct. Biol. 17, 412-418.
43. Beretta, G. L., Benedetti, V., Cossa, G., Assaraf, Y. G., Bram, E., Gatti, L., Corna, E., Carenini, N., Colangelo, D., Howell, S. B., Zunino, F. and Perego, P. (2010) Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. Biochem. Pharmacol. 79, 1108-1117.
44. Leffler, H., Carlsson, S., Hedlund, M., Qian, Y. and Poirier, F. (2004) Introduction to galectins. Glycoconj. J. 19, 433-440.
45. Fred Brewer, C. (2002) Binding and cross-linking properties of galectins. Biochim. Biophys. Acta. 1572, 255-262.
46. Liu, F. T. and Rabinovich GA. (2005) Galectins as modulators of tumour progression. Nat. Rev. Cancer 5, 29-41.
47. Camby, I., Le Mercier, M., Lefranc, F. and Kiss, R. (2006) Galectin-1: a small protein with major functions. Glycobiology 16, 137R-157.
48. Garner, O. B. and Baum, L. G. (2008) Galectin-glycan lattices regulate cell-surface glycoprotein organization and signaling. Biochem. Soc. Trans. 36, 1472-1477.
49. Wu, A. M., Lisowska, E., Duk, M. and Yang, Z. (2009) Lectins as tools in glycoconjugate research. Glycoconj. J. 26, 899-913.
50. Duverger, E., Frison, N., Roche, A. C. and Monsigny, M. (2003) Carbohydrate-lectin interactions assessed by surface plasmon resonance. Biochimie 85, 167-179.
51. Ahn, H. J., Kim, Y. S., Lee, C. H., Cho, E. W., Yoo, H. S., Kim, S. H. Ko, J. H. and Kim, S. J. (2011) Generation of antibodies recognizing an aberrant glycoform of human tissue inhibitor of metalloproteinase-1 (TIMP-1) using decoy immunization and phage display. J. Biotechnol. 151, 225-230.
52. Yoshida-Moriguchi, T., Yu, L., Stalnaker, S. H., Davis, S., Kunz, S., Madson, M., Oldstone, M. B., Schachter, H., Wells, L. and Campbell, K. P. (2010) O-mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding. Science 327, 88-92.